Otsuka Pharmaceutical Co.

Latest news

• Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Application (sNDA) for Rexulti (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease
  10 May 2023
• FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
  28 April 2023
• Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for Rexulti (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17
  6 January 2022
• FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
  24 April 2018
• FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
  13 November 2017
• U.S. FDA Approves Labeling Update of Rexulti (brexpiprazole) for Maintenance Treatment of Schizophrenia
  23 September 2016
• FDA Issues Complete Response Letter for Digital Medicine New Drug Application
  26 April 2016
• U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka and Proteus Digital Health
  10 September 2015
• FDA Approves Rexulti (brexpiprazole) for Schizophrenia and Adjunctive Treatment for Major Depressive Disorder
  10 July 2015
• Results of Phase III Study of Brexpiprazole in Adult Patients With Schizophrenia Published in American Journal of Psychiatry
  17 April 2015

Drugs Associated with Otsuka Pharmaceutical Co., Ltd

Otsuka Pharmaceutical Co., Ltd manufactures, markets and/or distributes more than 11 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.